



બંક ઓફ બારોડા  
Bank of Baroda

શ્રી **Shalendrakumar Singh**  
Name

કર્મચારી કોડ નં. **102720**  
Employee Code No.


  
જાહેર કરનાર  
Issuing Authority



  
કર્મચારી  
Signature of Holder



Health Check up  
Booking Confirmed  
Request(bobE12666),Package ☆  
Code-PKG10000476,  
Beneficiary Code-297343 Inbox

 **Mediwheel** 11 Mar   

to me, [customer care](#) ▾

 Show pictures

011-41195959

Dear **SHAIENDRA KUMAR SINGH** ,  
We are pleased to confirm your health checkup booking request with the following details.

**Hospital Package Name** : Mediwheel Full Body Health Checkup Male Above 40  
Mediwheel Full



Aashka Hospitals Ltd.

Between Sargasan and Reliance Cross Roads  
Sargasan, Gandhinagar - 382421, Gujarat, India  
Phone: 079-29750750, +91-7575006000 / 9000  
Emergency No.: +91-7575007707 / 9879752777  
www.aashkahospitals.in  
CIN: L85110GJ2012PLC072647

 **aashka**  
H O S P I T A L



DR. TAPAS RAVAL  
MBBS . D.O  
(FELLOW IN PHACO & MEDICAL  
RATINA)  
REG.NO.G-21350

UHID: 05P33590	Date:	Time:
Patient Name:	Age / Sex:	Height: 195 Weight: 80
History:	Common hepatic duct. Fibrous calcification 10x4 - 8x10 cm. Dm 10x4 cm.	
Allergy History:		
Nutritional Screening: Well-Nourished / Malnourished / Obese		
Examination:	G118 N26118 NTE (common) G118 G118 G118	
Diagnosis:	Colours vision. Normal Fibroblastoma	

Rx						
No	Dosage Form	Name of drug (IN BLOCK LETTERS ONLY)	Dose	Route	Frequency	Duration

Eye examination:

	RIGHT			LEFT		
	S	C	A	S	C	A
D	+0.50	+0.50	+1.80	+1.75	+1.75	+1.80
N	+1.75	+0.50	+1.80	+1.75	+1.75	+1.80

Other Advice:

*Christie Gullish*

Follow-up:

Consultant's Sign:

*R*

Aashka Hospitals Ltd.

Between Sargasan and Reliance Cross Roads  
Sargasan, Gandhinagar - 382421, Gujarat, India  
Phone: 079-29750750, +91-7575006000 / 9000  
Emergency No.: +91-7575007707 / 9879752777  
www.aashkahospitals.in  
CIN: L85110GJ2012PLC072647



**aashka**  
H O S P I T A L



DR. SEJAL J AMIN  
B.D.S, M.D.S (PERIODONTIST)  
IMPLANTOLOGIST  
REG NO: A-12942

UHID:	OSP83590	Date:	23/3/24	Time:	
Patient Name:	Shwetalendrakumar	Age / Sex:	57 / M	Height:	175
				Weight:	80
Chief Complain:					
History:	- Routine dental check up				
Allergy History:					
Nutritional Screening:	Well-Nourished / Malnourished / Obese				
Examination:					
Extra oral :	-				
Intra oral - Teeth Present :	Crem. Utilization present.				
Teeth Absent :	6 / 167				
Diagnosis:					

Rx

No	Dosage Form	Name of drug (IN BLOCK LETTERS ONLY)	Dose	Route	Frequency	Duration

Other Advice:

→ Full month Rehabilitation,  
→ Sewing

Follow-up:

Consultant's Sign:





## Dr. MAULIK VYAS

M.B.B.S., D.T.C.D., T.D.D.

Reg.no: G-0749

### CHEST PHYSICIAN, ALLERGY SPECIALIST and INTERVENTIONAL PULMONOLOGIST

NAME: SATLENDRA KUMAR SENSH.

Date: 23/3/24.

AGE: 51 yrs. SEX: M.

Pulse = 94/min

Height:

B.P. = 120/80 mm Hg.

Chief Complaints: Respiratory distress = 257 mg/dL

R.R. = 20/min

Fb = 226 mg/dL

Spo2 = 98%

LAL = 155 mg/dL

Temp. = (N)

R.B.S. = 148 mg/dL

Body built / Nutritional status: None.

Sleep cycle: (N)

Any known allergies: None

E.C.G.: (N)

K/C/O: - DM-II, HTN, Thyroid, Hyperlipidemia, Asthma, COPD, TB, Cancer, ILD, etc.

On the Tab. SIMSTAR 12 0-10 [P 4-5 yrs.]  
Tab. Penicillin 1-0-0

Provisional Diagnosis:

\*General Examination: -

Clubbing:

- Lymph node enlargement: None.

Cyanosis:

\*On Examination:-

Edema:

- Breath sounds: Normal Breath sound / Wheezing / Crackles / Stridor / Rhonchi / Plural friction rub.

- Chest movements: (M)

- Air entry: AE = BE.

Rx,

Tab. AMOXYC F 0-0-1 x 10 months.

Adv: 1) FTE FOR DURY"

2) Follow up after 10 months

3) Life style modification.

M.B.B.S.

**Advices:**

- 1) Chest X ray (PA),
  - 2) USG Abdomen ,
  - 3) HRCT thorax (P) / Contrast,
  - 4) Skin Prick test for allergy / Allergy Screening Tests (By IMMUNO-EIA)
  - 5) Pulmonary Function Test (PFT) with /without DLCO,
  - 6) Bronchoscopy (Flexible / Rigid),
  - 7) Plural fluid examination (Biochemical / Hematological / Bacteriological/TB-fungal culture/ Cytological),
  - 8) Sputum Examination (Routine / Microscopic / Microbiological),
  - 9) Blood investigations:-
    - CBC, PS For MP, CRP, ESR, SGPT, S. Creatinine, S.electrolytes, HIV, HBsAg, Dengue NS1, Urine(R/M) , Widal test, VDRL test, Liver Function test , Kidney Function test, Lipid profile, Thyroid profile (T3,T4,TSH).
    - ABG (Arterial blood gas),
    - D- Dimmer level,
    - Procalcitonin level,
  - \*Tumor markers :-
    - CEA (carcinoembryonic antigen),
    - Neuron specific enolase (NSE){ Small cell carcinoma),
    - SCC( Squamous cell carcinoma antigen ),
  - 10) Follow up after      days/months.
  - 11) Inform SOS.
  - 12) Admission.
- CTFRA 21-1 (Non small cell carcinoma),  
-Mesothelin (Malignant mesothelioma),

Dr. Manik Vyas

Shailendrakuar

701 Contrast 226 166 05

0459 LOT D 942 #

23.03.2024 11:58:01 AM  
AASHKA HOSPITAL LTD.  
SARGASAN  
GANDHINAGAR

Location: 1  
Order Number:  
Indication:  
Medication 1:  
Medication 2:  
Medication 3:


Room:

71 bpm  
-- / -- mmHg

Technician:  
Ordering Ph:  
Referring Ph:  
Attending Ph:

QRS : 76 ms  
QT / QTcBaz : 360 / 391 ms  
PR : 146 ms  
P : 84 ms  
RR / PP : 846 / 845 ms  
P / QRS / T : 55 / 43 / 25 degrees

Normal sinus rhythm with sinus arrhythmia  
Normal ECG







## LABORATORY REPORT



Name : **SHAIENDRAKUMAR SINGH** Sex/Age : **Male / 51 Years** Case ID : **40302200641**  
Ref.By : **HOSPITAL** Dis. At : Pt. ID : **3455383**  
Bill. Loc. : **Aashka hospital** Pt. Loc :  
Reg Date and Time : **23-Mar-2024 10:41** Sample Type : Mobile No :  
Sample Date and Time : **23-Mar-2024 10:41** Sample Coll. By : Ref Id1 : **OSP33590**  
Report Date and Time : Acc. Remarks : **Normal** Ref Id2 : **O232411332**

### Abnormal Result(s) Summary

Test Name	Result Value	Unit	Reference Range
<b>Blood Glucose Fasting &amp; Postprandial</b>			
Plasma Glucose - F	145.72	mg/dL	70.0 - 100
Plasma Glucose - PP	249.67	mg/dL	70.0 - 140.0
<b>Glyco Hemoglobin (HbA1c)</b>			
HbA1C	6.24	% of total Hb	<5.7: Normal 5.7-6.4: Prediabetes >=6.5: Diabetes
<b>Haemogram (CBC)</b>			
RBC (Electrical Impedance)	4.42	millions/cu mm	4.50 - 5.50
PCV(Calc)	39.69	%	40.00 - 50.00
<b>Lipid Profile</b>			
Cholesterol	237.93	mg/dL	110 - 200
HDL Cholesterol	36.7	mg/dL	48 - 77
Triglyceride	226.53	mg/dL	<150
VLDL	45.31	mg/dL	10 - 40
Chol/HDL	6.48	0 - 4.1	0 - 4.1
LDL Cholesterol	155.92	mg/dL	0.00 - 100.00

### Abnormal Result(s) Summary End

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)





## LABORATORY REPORT



Name : **SHAILENDRAKUMAR SINGH** Sex/Age : **Male / 51 Years** Case ID : **40302200641**  
 Ref.By : **HOSPITAL** Dis. At : Pt. ID : **3455383**  
 Bill. Loc. : **Aashka hospital** Pt. Loc :

Reg Date and Time : **23-Mar-2024 10:41** Sample Type : **Whole Blood EDTA** Mobile No :  
 Sample Date and Time : **23-Mar-2024 10:41** Sample Coll. By : Ref Id1 : **OSP33590**  
 Report Date and Time : **23-Mar-2024 11:04** Acc. Remarks : **Normal** Ref Id2 : **O232411332**

TEST	RESULTS	UNIT	BIOLOGICAL REF. INTERVAL	REMARKS
------	---------	------	--------------------------	---------

### HAEMOGRAM REPORT

#### HB AND INDICES

Haemoglobin	13.3	G%	13.00 - 17.00	
RBC (Electrical Impedance)	L 4.42	millions/cumm	4.50 - 5.50	
PCV(Calc)	L 39.69	%	40.00 - 50.00	
MCV (RBC histogram)	89.8	fL	83.00 - 101.00	
MCH (Calc)	30.1	pg	27.00 - 32.00	
MCHC (Calc)	33.5	gm/dL	31.50 - 34.50	
RDW (RBC histogram)	14.30	%	11.00 - 16.00	

#### TOTAL AND DIFFERENTIAL WBC COUNT (Flowcytometry)

	[%]	EXPECTED VALUES	UNIT	EXPECTED VALUES	EXPECTED VALUES
Total WBC Count	8440	4000.00 - 10000.00	/ $\mu$ L	4000.00 - 10000.00	
Neutrophil	60.0	40.00 - 70.00	%	40.00 - 70.00	[Abs] 5064 / $\mu$ L 2000.00 - 7000.00
Lymphocyte	34.0	20.00 - 40.00	%	20.00 - 40.00	/ $\mu$ L 2870 / $\mu$ L 1000.00 - 3000.00
Eosinophil	2.0	1.00 - 6.00	%	1.00 - 6.00	/ $\mu$ L 169 / $\mu$ L 20.00 - 500.00
Monocytes	4.0	2.00 - 10.00	%	2.00 - 10.00	/ $\mu$ L 338 / $\mu$ L 200.00 - 1000.00
Basophil	0.0	0.00 - 2.00	%	0.00 - 2.00	/ $\mu$ L 0 / $\mu$ L 0.00 - 100.00

#### PLATELET COUNT (Optical)

Platelet Count	214000	/ $\mu$ L	150000.00 - 410000.00
Neut/Lympho Ratio (NLR)	1.76		0.78 - 3.53

#### SMEAR STUDY

**RBC Morphology** Normocytic Normochromic RBCs.  
**WBC Morphology** Total WBC count within normal limits.  
**Platelet** Platelets are adequate in number.  
**Parasite** Malarial Parasite not seen on smear.

Note: (LL-VeryLow, L-Low, H-High, HH-VeryHigh ,A-Abnormal)



**Dr. Shreya Shah**  
M.D. (Pathologist)

Page 2 of 14

Printed On : 23-Mar-2024 14:54









## LABORATORY REPORT



Name : SHAILENDRAKUMAR SINGH

Sex/Age : Male / 51 Years Case ID : 40302200641

Ref.By : HOSPITAL

Dis. At : Pt. ID : 3455383

Bill. Loc. : Aashka hospital

Pt. Loc :

Reg Date and Time : 23-Mar-2024 10:41

Sample Type : Whole Blood EDTA

Mobile No :

Sample Date and Time : 23-Mar-2024 10:41

Sample Coll. By :

Ref Id1 : OSP33590

Report Date and Time : 23-Mar-2024 12:54

Acc. Remarks : Normal

Ref Id2 : O232411332

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

ESR  
*Westergren Method*

10

mm after 1hr 3 - 20

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shreya Shah  
M.D. (Pathologist)

Page 3 of 14

Printed On : 23-Mar-2024 14:54







## LABORATORY REPORT

Name : **SHAILENDRAKUMAR SINGH**

Ref.By : **HOSPITAL**

Bill. Loc. : **Aashka hospital**

Sex/Age : **Male / 51 Years**

Case ID : **40302200641**

Dis. At :

Pt. ID : **3455383**

Pt. Loc :

Reg Date and Time : **23-Mar-2024 10:41**

Sample Type : **Whole Blood EDTA**

Mobile No :

Sample Date and Time : **23-Mar-2024 10:41**

Sample Coll. By :

Ref Id1 : **OSP33590**

Report Date and Time : **23-Mar-2024 11:02**

Acc. Remarks : **Normal**

Ref Id2 : **O232411332**

TEST

RESULTS

UNIT BIOLOGICAL REF RANGE

REMARKS

### HAEMATOTOLOGY INVESTIGATIONS

### BLOOD GROUP AND RH TYPING (Erythrocyte Magnetized Technology) (Both Forward and Reverse Group)

ABO Type

**B**

Rh Type

**POSITIVE**

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)



**Dr. Shreya Shah**

M.D. (Pathologist)

Page 4 of 14

Printed On : 23-Mar-2024 14:54







## LABORATORY REPORT



Name : **SHAIENDRAKUMAR SINGH**

Ref.By : HOSPITAL

Bill. Loc. : Aashka hospital

Sex/Age : Male / 51 Years

Case ID : 40302200641

Dis. At :

Pt. ID : 3455383

Pt. Loc :

Reg Date and Time : 23-Mar-2024 10:41

Sample Type : Plasma Fluoride F, Plasma Fluoride PP

Mobile No :

Sample Date and Time : 23-Mar-2024 10:41

Sample Coll. By :

Ref Id1 : OSP33590

Report Date and Time : 23-Mar-2024 14:44

Acc. Remarks : Normal

Ref Id2 : O232411332

TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

### BIOCHEMICAL INVESTIGATIONS

#### Blood Glucose Level (Fasting & Post Prandial)

Plasma Glucose - F	H	145.72	mg/dL	70.0 - 100
Plasma Glucose - PP <i>Photometric, Hexokinase</i>	H	249.67	mg/dL	70.0 - 140.0

Reference range has been changed as per recent guidelines of ISPAD 2018.

<100 mg/dL : Normal level

100-<126 mg/dL: Impaired fasting glucoseeer guidelines

>=126 mg/dL: Probability of Diabetes, Confirm as per guidelines

Note:(LL-Very/Low,L-Low,H-High,HH-Very/High ,A-Abnormal)

  
Dr. Shreya Shah

M.D. (Pathologist)

Printed On : 23-Mar-2024 14:54

Page 5 of 14



1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that this is crucial for ensuring transparency and accountability in the organization's operations.

2. The second part of the document outlines the various methods and tools used to collect and analyze data. It highlights the need for consistent data collection procedures and the use of advanced analytical techniques to derive meaningful insights from the data.

3. The third part of the document focuses on the implementation of data-driven decision-making processes. It provides a detailed overview of the steps involved in identifying key performance indicators (KPIs) and using data to inform strategic decisions.

4. The fourth part of the document discusses the challenges and opportunities associated with data management and analysis. It addresses issues such as data quality, privacy, and security, while also highlighting the potential for data to drive innovation and growth in the organization.

5. The fifth part of the document concludes with a summary of the key findings and recommendations. It emphasizes the importance of ongoing monitoring and evaluation to ensure that the data-driven approach remains effective and relevant in a rapidly changing business environment.

6. The final part of the document provides a list of references and resources for further reading. It includes links to relevant articles, books, and industry reports that provide additional context and information on the topics discussed in the document.



## LABORATORY REPORT



Name : SHAILENDRAKUMAR SINGH

Ref.By : HOSPITAL

Bill. Loc. : Aashka hospital

Sex/Age : Male / 51 Years

Case ID : 40302200641

Dis. At :

Pt. ID : 3455383

Pt. Loc :

Reg Date and Time : 23-Mar-2024 10:41

Sample Type : Whole Blood EDTA

Sample Date and Time : 23-Mar-2024 10:41

Sample Coll. By :

Mobile No :

Report Date and Time : 23-Mar-2024 11:21

Acc. Remarks : Normal

Ref Id1 : OSP33590

Ref Id2 : O232411332

### TEST

RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

### Glycated Haemoglobin Estimation

HbA1C H **6.24**\*

% of total Hb <5.7: Normal  
5.7-6.4: Prediabetes  
>=6.5: Diabetes

**Estimated Avg Glucose (3 Mths)** 132.39

mg/dL

Not available

Please Note change in reference range as per ADA 2021 guidelines.

#### Interpretation :

HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycaemic control. Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia. Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients. Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA. In such circumstances glycaemic control can be monitored using plasma glucose levels or serum Fructosamine. The A1c target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.

Note: (LL-Very Low, L-Low, H-High, HH-Very High ,A-Abnormal)

Dr. Shreya Shah

M.D. (Pathologist)

Page 6 of 14

Printed On : 23-Mar-2024 14:54



Neuberg Diagnostics Private Limited

Laboratory : "KEDAR" Opposite Krupa Petrol Pump, Near Parimal Garden, Ahmedabad - 380006 ☎ 079-40408181 / 61618181

Regd. Office : Plot No. 7, Industrial Estate, Rajiv Gandhi Salai, Perungudi, Chennai - 600096, Tamil Nadu, India. | CIN - U85300TN2017PTC114099

✉ contact@neubergsupratech.com

🌐 www.neubergsupratech.com







## LABORATORY REPORT



Name : **SHAIENDRAKUMAR SINGH**

Ref.By : **HOSPITAL**

Bill. Loc. : **Aashka hospital**

Sex/Age : **Male / 51 Years**

Dis. At :

Case ID : **40302200641**

Pt. ID : **3455383**

Pt. Loc :

Reg Date and Time : **23-Mar-2024 10:41**

Sample Type : **Serum**

Mobile No :

Sample Date and Time : **23-Mar-2024 10:41**

Sample Coll. By :

Ref Id1 : **OSP33590**

Report Date and Time : **23-Mar-2024 13:32**

Acc. Remarks : **Normal**

Ref Id2 : **O232411332**

### TEST

RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

### BIOCHEMICAL INVESTIGATIONS

#### Lipid Profile

<b>Cholesterol</b> <i>Colorimetric, CHOD-POD</i>	H	<b>237.93</b>	mg/dL	110 - 200
<b>HDL Cholesterol</b>	L	<b>36.7</b>	mg/dL	48 - 77
<b>Triglyceride</b> <i>Glycerol Phosphate Oxidase</i>	H	<b>226.53</b>	mg/dL	<150
<b>VLDL</b> <i>Calculated</i>	H	<b>45.31</b>	mg/dL	10 - 40
<b>Chol/HDL</b> <i>Calculated</i>	H	<b>6.48</b>		0 - 4.1
<b>LDL Cholesterol</b> <i>Calculated</i>	H	<b>155.92</b>	mg/dL	0.00 - 100.00

#### NEW ATP III GUIDELINES (MAY 2001), MODIFICATION OF NCEP

LDL CHOLESTEROL	CHOLESTEROL	HDL CHOLESTEROL	TRIGLYCERIDES
Optimal <100	Desirable <200	Low <40	Normal <150
Near Optimal 100-129	Border Line 200-239	High >60	Border High 150-199
Borderline 130-159	High >240		High 200-499
High 160-189			

- LDL Cholesterol level is primary goal for treatment and varies with risk category and assessment
- For LDL Cholesterol level Please consider direct LDL value
- Risk assessment from HDL and Triglyceride has been revised. Also LDL goals have changed.
- Detail test interpretation available from the lab
- All tests are done according to NCEP guidelines and with FDA approved kits.
- LDL Cholesterol level is primary goal for treatment and varies with risk category and assessment

Note: (L-VeryLow, L-Low, H-High, HH-VeryHigh ,A-Abnormal)



**Dr. Shreya Shah**  
M.D. (Pathologist)

Page 7 of 14

Printed On : 23-Mar-2024 14:54



1. The first part of the document discusses the importance of maintaining accurate records of all transactions.

2. This section outlines the various methods used to collect and analyze data.

3. The following table provides a summary of the key findings from the study.

4. The data shows a significant increase in sales over the period studied, particularly in the latter half.

5. It is concluded that the implemented strategies have been highly effective in driving growth.

6. Further research is needed to explore the long-term sustainability of these results.

7.

8. The overall trend indicates a positive outlook for the future of the industry.

9. The study highlights the need for continuous monitoring and adaptation to market changes.

10. The results suggest that a focus on customer engagement is crucial for long-term success.

11. The data also shows that digital marketing efforts have yielded significant returns.

12. The study identifies several key areas for future investment and development.

13. The findings support the hypothesis that innovation leads to increased market share.

14. The research provides valuable insights into the competitive landscape.

15. The study concludes that a data-driven approach is essential for strategic decision-making.

16. The analysis reveals a strong correlation between marketing spend and revenue growth.

17. The study emphasizes the importance of cross-functional collaboration.

18. The results indicate that the current market conditions are favorable for expansion.

19. The study suggests that targeted advertising can significantly improve conversion rates.

20. The findings provide a clear roadmap for future business development.

21.

22. The study also notes the challenges faced by small businesses in a competitive market.

23. The data shows that customer loyalty programs can be highly effective.

24. The study highlights the role of technology in streamlining operations.

25. The findings suggest that a strong brand identity is a key differentiator.

26. The study concludes that the industry is on a path of steady growth.

27. The research provides a comprehensive overview of the current market state.

28. The study identifies the need for a more integrated marketing strategy.

29. The findings support the idea that customer-centricity is the key to success.

30. The study provides a detailed analysis of the factors influencing market performance.

31. The research offers practical recommendations for business owners.

32. The study concludes that the future is bright for businesses that embrace change.

33. The findings are consistent with previous research in the field.

34. The study provides a solid foundation for further exploration.

35. The research is a valuable resource for anyone interested in business strategy.

36. The study highlights the importance of staying up-to-date on market trends.

37. The findings suggest that a proactive approach is necessary for long-term success.

38. The study provides a clear picture of the current business environment.

39. The research offers a wealth of insights into the complexities of the market.

40. The study concludes that the future is full of opportunities for growth.



## LABORATORY REPORT



Name : SHAIENDRAKUMAR SINGH		Sex/Age : Male / 51 Years	Case ID : 40302200641
Ref.By : HOSPITAL		Dis. At :	Pt. ID : 3455383
Bill. Loc. : Aashka hospital			Pt. Loc :
Reg Date and Time : 23-Mar-2024 10:41	Sample Type : Serum	Mobile No :	
Sample Date and Time : 23-Mar-2024 10:41	Sample Coll. By :	Ref Id1 : OSP33590	
Report Date and Time : 23-Mar-2024 13:32	Acc. Remarks : Normal	Ref Id2 : O232411332	

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

### BIOCHEMICAL INVESTIGATIONS

#### Liver Function Test

<b>S.G.P.T.</b> <i>UV with P5P</i>	22.22	U/L	16 - 63	
<b>S.G.O.T.</b> <i>UV with P5P</i>	16.71	U/L	15 - 37	
<b>Alkaline Phosphatase</b> <i>Enzymatic, PNPP-AMP</i>	105.57	U/L	46 - 116	
<b>Gamma Glutamyl Transferase</b> <i>L-Gamma-glutamyl-3-carboxy-4-nitroanilide Substrate</i>	36.28	U/L	0 - 55	
<b>Proteins (Total)</b> <i>Colorimetric, Biuret</i>	8.24	gm/dL	6.40 - 8.30	
<b>Albumin</b> <i>Bromocresol purple</i>	5.00	gm/dL	3.4 - 5	
<b>Globulin</b> <i>Calculated</i>	3.24	gm/dL	2 - 4.1	
<b>A/G Ratio</b> <i>Calculated</i>	1.5		1.0 - 2.1	
<b>Bilirubin Total</b> <i>Photometry</i>	0.38	mg/dL	0.3 - 1.2	
<b>Bilirubin Conjugated</b> <i>Diazoitization reaction</i>	0.31	mg/dL	0 - 0.50	
<b>Bilirubin Unconjugated</b> <i>Calculated</i>	0.07	mg/dL	0 - 0.8	

Note: (LL-VeryLow, L-Low, H-High, HH-VeryHigh ,A-Abnormal)

**Dr. Shreya Shah**  
M.D. (Pathologist)

Page 8 of 14

Printed On : 23-Mar-2024 14:54



1. The first part of the document discusses the importance of maintaining accurate records of all transactions.

2. It is essential to ensure that all entries are dated and clearly describe the nature of the transaction.

3. The second part of the document outlines the various methods used to collect and analyze data from different sources.

4. These methods include direct observation, interviews, and the use of specialized equipment.

5. The results of these analyses are then used to identify trends and patterns in the data.

)

6. The following table provides a summary of the key findings from the study.

Category	Value
Item 1	12.5
Item 2	8.7
Item 3	15.2
Item 4	9.1
Item 5	11.3
Item 6	7.8
Item 7	13.6
Item 8	10.4
Item 9	14.9
Item 10	6.5
Item 11	12.1
Item 12	9.3
Item 13	11.7
Item 14	8.9
Item 15	13.4
Item 16	10.6
Item 17	14.2
Item 18	7.6
Item 19	12.8
Item 20	9.5

)

7. The data indicates a significant correlation between the variables studied.

8. Further research is needed to explore the underlying causes of these trends.

9. The conclusions drawn from this study have important implications for the field.

10. The authors thank the participants and funding agencies for their support.

11. The document concludes with a list of references and a list of authors.

12. The authors are available for further inquiries at the contact information provided.

13. The document is published in the journal of Applied Research in Psychology.

14. The volume number is 15, and the issue number is 3.

15. The publication date is 2023.



## LABORATORY REPORT



Name : SHAILENDRAKUMAR SINGH

Ref.By : HOSPITAL

Bill. Loc. : Aashka hospital

Sex/Age : Male / 51 Years

Case ID : 40302200641

Dis. At :

Pt. ID : 3455383

Pt. Loc :

Reg Date and Time : 23-Mar-2024 10:41

Sample Type : Serum

Sample Date and Time : 23-Mar-2024 10:41

Sample Coll. By :

Mobile No :

Report Date and Time : 23-Mar-2024 13:32

Acc. Remarks : Normal

Ref Id1 : OSP33590

Ref Id2 : O232411332

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

BUN (Blood Urea Nitrogen)  
GLDH

8.5

mg/dL

8.40 - 25.70

Uric Acid  
Uricase

5.66

mg/dL

3.5 - 7.2

Creatinine

0.88

mg/dL

0.50 - 1.50

Note: (LL-VeryLow, L-Low, H-High, HH-VeryHigh ,A-Abnormal)

Dr. Shreya Shah  
M.D. (Pathologist)

Page 9 of 14

Printed On : 23-Mar-2024 14:54



Neuberg Diagnostics Private Limited





## LABORATORY REPORT

Name : **SHAILENDRAKUMAR SINGH**

Ref.By : HOSPITAL

Bill. Loc. : Aashka hospital

Sex/Age : Male / 51 Years

Case ID : 40302200641

Dis. At :

Pt. ID : 3455383

Pt. Loc :

Reg Date and Time : 23-Mar-2024 10:41

Sample Type : Serum

Mobile No :

Sample Date and Time : 23-Mar-2024 10:41

Sample Coll. By :

Ref Id1 : OSP33590

Report Date and Time : 23-Mar-2024 11:50

Acc. Remarks : Normal

Ref Id2 : O232411332

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

### Thyroid Function Test

Triiodothyronine (T3)	80.82	ng/dL	40 - 181	
Thyroxine (T4) C/M/A	6.39	ng/dL	4.87 - 11.72	
TSH C/M/A	3.64	µIU/mL	0.4 - 4.2	

### INTERPRETATIONS

- Circulating TSH measurement has been used for screening for euthyroidism, screening and diagnosis for hyperthyroidism & hypothyroidism. Suppressed TSH (<0.01 µIU/mL) suggests a diagnosis of hyperthyroidism and elevated concentration (>7 µIU/mL) suggest hypothyroidism. TSH levels may be affected by acute illness and several medications including dopamine and glucocorticoids. Decreased (low or undetectable) in Graves disease. Increased in TSH secreting pituitary adenoma (secondary hyperthyroidism), PRTH and in hypothalamic disease thyrotropin (tertiary hyperthyroidism). Elevated in hypothyroidism (along with decreased T4) except for pituitary & hypothalamic disease.
- Mild to modest elevations in patient with normal T3 & T4 levels indicates impaired thyroid hormone reserves & incipient hypothyroidism (subclinical hypothyroidism).
- Mild to modest decrease with normal T3 & T4 indicates subclinical hyperthyroidism.
- Degree of TSH suppression does not reflect the severity of hyperthyroidism, therefore, measurement of free thyroid hormone levels is required in patient with a suppressed TSH level.

### CAUTIONS

Sick, hospitalized patients may have falsely low or transiently elevated thyroid stimulating hormone. Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or imaging procedure, may have circulating antianimal antibodies present. These antibodies may interfere with the assay reagents to produce unreliable results.

### TSH ref range in pregnancy

First trimester	0.24 - 2.00
Second trimester	0.43-2.2
Third trimester	0.8-2.5

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

  
Dr. Shreya Shah

M.D. (Pathologist)

Page 10 of 14

Printed On : 23-Mar-2024 14:54



Neuberg Diagnostics Private Limited

Laboratory : "KEDAR" Opposite Krupa Peirol Pump, Near Parimal Garden,  
Ahmedabad - 380006 ☎ 079-40408181 / 61618181

✉ contact@neubergsupratech.com

Regd. Office : Plot No. 7, Industrial Estate, Rajiv Gandhi Salai, Perungudi,  
Chennai - 600096, Tamil Nadu, India. | CIN - U85300TN2017PTCT114099

🌐 www.neubergsupratech.com







## LABORATORY REPORT



Name : SHAILENDRAKUMAR SINGH

Ref.By : HOSPITAL

Bill. Loc. : Aashka hospital

Sex/Age : Male / 51 Years

Dis. At :

Case ID : 40302200641

Pt. ID : 3455383

Pt. Loc :

Reg Date and Time : 23-Mar-2024 10:41

Sample Type : Serum

Sample Date and Time : 23-Mar-2024 10:41

Sample Coll. By :

Mobile No :

Ref Id1 : OSP33590

Report Date and Time : 23-Mar-2024 11:50

Acc. Remarks : Normal

Ref Id2 : O232411332

**Interpretation Note:**

Ultra sensitive-thyroid-stimulating hormone (TSH) is a highly effective screening assay for thyroid disorders. In patients with an intact pituitary-thyroid axis, s-TSH provides a physiologic indicator of the functional level of thyroid hormone activity. Increased s-TSH indicates inadequate thyroid hormone, and suppressed s-TSH indicates excess thyroid hormone. Transient s-TSH abnormalities may be found in seriously ill, hospitalized patients, so this is not the ideal setting to assess thyroid function. However, even in these patients, s-TSH works better than total thyroxine (an alternative screening test). When the s-TSH result is abnormal, appropriate follow-up tests T4 & free T3 levels should be performed. If TSH is between 5.0 to 10.0 & free T4 & free T3 levels are normal then it is considered as subclinical hypothyroidism which should be followed up after 4 weeks & if TSH is > 10 & free T4 & free T3 level are normal then it is considered as overt hypothyroidism.

Serum triiodothyronine (T3) levels often are depressed in sick and hospitalized patients, caused in part by the biochemical shift to the production of reverse T3. Therefore, T3 generally is not a reliable predictor of hypothyroidism. However, in a small subset of hyperthyroid patients, hyperthyroidism may be caused by overproduction of T3 (T3 toxicosis). To help diagnose and monitor this subgroup, T3 is measured on all specimens with suppressed s-TSH and normal FT4 concentrations.

Normal ranges of TSH & thyroid hormones vary according trimester in pregnancy.

TSH ref range in Pregnancy

First trimester

Second trimester

Third trimester

Reference range (microIU/ml)

0.24 - 2.00

0.43-3.2

0.6-2.5

	T3	T4	TSH
Normal Thyroid function	N	N	N
Primary Hypothyroidism	↑	↑	↓
Secondary Hypothyroidism	↑	↑	↑
Grave's Thyroiditis	↑	↑	↑
T3 Thyrotoxicosis	↓	N	N/↓
Primary Hypothyroidism	↓	↓	↑
Secondary Hypothyroidism	↓	↓	↓
Subclinical Hypothyroidism	N	N	↑
Patient on treatment	N	N/↑	↓

Note:(L-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Shreya Shah

M.D. (Pathologist)

Page 11 of 14

Printed On : 23-Mar-2024 14:54



1. The first part of the document discusses the importance of maintaining accurate records.

2. It is essential to ensure that all data is entered correctly and consistently.

3. Regular audits should be conducted to verify the integrity of the information.

4. Proper labeling and organization of files are crucial for easy retrieval.

5. The following table provides a detailed overview of the current status.

Category	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	Item 9	Item 10	Item 11	Item 12	Item 13	Item 14	Item 15	Item 16	Item 17	Item 18	Item 19	Item 20
Group A	10	20	30	40	50	60	70	80	90	100	110	120	130	140	150	160	170	180	190	200
Group B	15	25	35	45	55	65	75	85	95	105	115	125	135	145	155	165	175	185	195	205
Group C	20	30	40	50	60	70	80	90	100	110	120	130	140	150	160	170	180	190	200	210

6. The data indicates a steady increase over the period.

7. Further analysis is required to identify trends.



## LABORATORY REPORT

Name : **SHAILENDRAKUMAR SINGH**

Ref.By : HOSPITAL

Bill. Loc. : Aashka hospital

Sex/Age : Male / 51 Years

Dis. At :

Pt. Loc :

Case ID : 40302200641

Pt. ID : 3455383

Pt. Loc :

Reg Date and Time : 23-Mar-2024 10:41

Mobile No :

Sample Type : Serum

Ref Id1 : OSP33590

Sample Date and Time : 23-Mar-2024 10:41

Ref Id2 : O232411332

Report Date and Time : 23-Mar-2024 14:04

Acc. Remarks : Normal

### TEST

RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

### Prostate Specific Antigen (PSA)

Prostate Specific Antigen 0.226 ng/mL 0.00 - 4.00

	0 - 0.5 *(ng/mL)	>0.5 - 2.5 (ng/mL)	>2.5 - 5.0 (ng/mL)	>5.0 - 10 (ng/mL)	>10 (ng/mL)
Healthy Males	87.2	12.8	0.0	0.0	0.0
BPH	51.9	42.9	4.2	0.5	0.5
Stage A Prostate Cancer	38.5	42.3	11.5	3.8	3.8
Stage B Prostate Cancer	23.9	66.7	7.5	0.0	0.0

-% of population

### Use :

The total PSA test and digital rectal exam (DRE) are used together to help determine the need for a prostate biopsy. The goal of screening is to minimize unnecessary biopsies and to detect clinically significant prostate cancer while it is still confined to the prostate.

Clinical significance of elevated levels of PSA are associated with prostate cancer, but they may also be seen with prostatitis and benign prostatic hyperplasia (BPH). Mild to moderately increased concentrations of PSA may be seen in those of African American heritage, and levels tend to increase in all men as they age.

Prostate biopsy is required for the diagnosis of cancer.

### FREE PSA:TOTAL PSA

Males:

When Total PSA concentration is in the range of 4.0-10.0 ng/mL:

Free PSA/total PSA ratio	Probability of cancer			
	50-55 years	60-65 years	> or =70 years	
< or =0.10	45%	56%	65%	
0.11-0.18	27%	34%	41%	
0.19-0.25	15%	24%	30%	
>0.25	9%	12%	16%	

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

**Dr. Sandip Shah**

M.D. (Path. & Bact.)  
Consultant Pathologist

Page 12 of 14

**Dr. Aakash Shah**

MD. Path.  
Consultant Pathologist

**Dr. Sandip Shah**

M.D. (Path. & Bact.)  
Consultant Pathologist

Printed On : 23-Mar-2024 14:54







## LABORATORY REPORT



Name : SHAILENDRAKUMAR SINGH

Sex/Age : Male / 51 Years Case ID : 40302200641

Ref.By : HOSPITAL

Dis. At :

Pt. ID : 3455383

Bill. Loc. : Aashka hospital

Pt. Loc :

Reg Date and Time : 23-Mar-2024 10:41

Sample Type : Spot Urine

Mobile No :

Sample Date and Time : 23-Mar-2024 10:41

Sample Coll. By :

Ref Id1 : OSP33590

Report Date and Time : 23-Mar-2024 11:57

Acc. Remarks : Normal

Ref Id2 : O232411332

TEST	RESULTS	UNIT	BIOLOGICAL REF RANGE	REMARKS
------	---------	------	----------------------	---------

### URINE EXAMINATION (STRIP METHOD AND FLOWCYTOMETRY)

#### Physical examination

Colour : Pale yellow

Transparency : Clear

#### Chemical Examination By Sysmex UC-3500

Sp. Gravity : >1.025

1.005 - 1.030

pH : <5.5

5 - 8

#### Leucocytes (ESTERASE)

Negative

Negative

Protein

Negative

Negative

Glucose

Negative

Negative

Ketone Bodies Urine

Negative

Negative

Urobilinogen

Negative

Negative

Bilirubin

Negative

Negative

Blood

Negative

Negative

Nitrite

Negative

Negative

#### Flowcytometric Examination By Sysmex UF-5000

Leucocyte : Nil

/HPF

Nil

Red Blood Cell

Nil

/HPF

Nil

Epithelial Cell

Present +

Present(+)

Bacteria

Nil

/HPF

Nil

Yeast

Nil

/HPF

Nil

Cast

Nil

/HPF

Nil

Crystals

Nil

/HPF

Nil

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)



Dr. Shreya Shah

M.D. (Pathologist)

Printed On : 23-Mar-2024 14:54







## LABORATORY REPORT

Name : **SHAILENDRAKUMAR SINGH**

Ref.By : HOSPITAL

Bill. Loc. : Aashka hospital

Sex/Age : Male / 51 Years

Dis. At :

Case ID : 40302200641

Pt. ID : 3455383

Pt. Loc :

Reg Date and Time : 23-Mar-2024 10:41 Sample Type : Spot Urine

Sample Date and Time : 23-Mar-2024 10:41 Sample Coll. By :

Mobile No :

Report Date and Time : 23-Mar-2024 11:57 Acc. Remarks : Normal

RefId1 : OSP33590

RefId2 : O232411332

Parameter	Unit	Expected value	Result/Notations			
			Trace	+	++	+++
pH	-	4.6-8.0				++++
SG	-	1.003-1.035				
Protein	mg/dL	Negative (<10)	10	25	75	150
Glucose	mg/dL	Negative (<30)	30	50	100	300
Bilirubin	mg/dL	Negative (0.2)	0.2	1	3	6
Ketone	mg/dL	Negative (<5)	5	15	50	150
Urobilinogen	mg/dL	Negative (<1)	1	4	8	12

Parameter	Unit	Expected value	Result/Notations			
			Trace	+	++	+++
Leukocytes (Strip)	/micro L	Negative (<10)	10	25	100	500
Nitrite (Strip)	-	Negative	-	-	-	-
Erythrocytes (Strip)	/micro L	Negative (<5)	10	25	50	150
Pus cells (Microscopic)	/hpf	<5	-	-	-	-
Red blood cells (Microscopic)	/hpf	<2	-	-	-	-
Cast (Microscopic)	/lpf	<2	-	-	-	-

----- End Of Report -----

# For test performed on specimens received or collected from non-NSRL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. NSRL will be responsible Only for the analytical part of test carried out. All other responsibility will be of referring Laboratory.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

**Dr. Shreya Shah**  
M.D. (Pathologist)

Page 14 of 14

Printed On : 23-Mar-2024 14:54







PATIENT NAME: SHAILENDRA KUMAR SINGH

GENDER/AGE: Male / 51 Years

DOCTOR: DR. HASIT JOSHI

OPDNO: OSP33590

DATE: 23/03/24

**2D-ECHO**

MITRAL VALVE : MINIMALLY SCLEROSED  
AORTIC VALVE : MINIMALLY SCLEROSED  
TRICUSPID VALVE : NORMAL  
PULMONARY VALVE : NORMAL  
AORTA : 33mm  
LEFT ATRIUM : 34mm  
LV Dd / Ds : 41/27mm EF 61%  
IVS / LVPW / D : 12.3/12.3mm BORDERLINE LVH  
IVS : INTACT  
IAS : INTACT  
RA : NORMAL  
RV : NORMAL  
PA : NORMAL  
PERICARDIUM : NORMAL  
VEL : PEAK MEAN  
M/S : Gradient mm Hg Gradient mm Hg  
MITRAL : 1/0.9m/s  
AORTIC : 1.2m/s  
PULMONARY : 0.9m/s  
COLOUR DOPPLER : NO MR/AR/TR  
RVSP :  
CONCLUSION : BORDERLINE LVH;  
NORMAL LV FUNCTION.

ADV: TMT

CARDIOLOGIST

DR. HASIT JOSHI (9825012235)





**Aashka Hospitals Ltd.**

Between Sargasan and Reliance Cross Roads  
Sargasan, Gandhinagar - 382421. Gujarat, India  
Phone: 079-29750750, +91-7575006000 / 9000  
Emergency No.: +91-7575007707 / 9879752777  
[www.aashkahospitals.in](http://www.aashkahospitals.in)  
CIN: L85110GJ2012PLC072647

 **aashka**  
H O S P I T A L



PATIENT NAME: SHAILENDRA KUMAR SINGH

GENDER/AGE: Male / 51 Years

DOCTOR:

OPDNO: OSP33590

DATE: 23/03/24

### X-RAY CHEST PA

Both lung fields show increased broncho-vascular markings.  
No evidence of **collapse, consolidation, mediastinal lymph adenopathy, soft tissue infiltration or pleural effusion** is seen.  
Both hilar shadows and C.P. angles are normal.  
Heart shadow appears normal in size. Aorta appears normal.  
Bony thorax and both domes of diaphragm appear normal.  
No evidence of cervical rib is seen on either side.

  
**DR. SNEHAL PRAJAPATI**  
CONSULTANT RADIOLOGIST



**Aashka Hospitals Ltd.**

Between Sargasan and Reliance Cross Roads  
Sargasan, Gandhinagar - 382421, Gujarat, India  
Phone: 079-29750750, +91-7575006000 / 9000  
Emergency No.: +91-7575007707 / 9879752777  
[www.aashkahospitals.in](http://www.aashkahospitals.in)  
CIN: L85110GJ2012PLC072647

 **aashka**  
H O S P I T A L



**PATIENT NAME: SHAILENDRA KUMAR SINGH**

**GENDER/AGE: Male / 51 Years**

**DATE: 23/03/24**

**DOCTOR:**

**OPDNO: OSP33590**

### SONOGRAPHY OF ABDOMEN AND PELVIS

**LIVER:** Liver appears normal in size and shows raised parenchymal echoes suggest fatty liver. No evidence of focal or diffuse lesion is seen. No evidence of dilated IHBR is seen. Intrahepatic portal radicles appear normal. No evidence of solid or cystic mass lesion is seen.

**GALL BLADDER:** Gall bladder is physiologically distended and appears normal. No evidence of calculus or changes of cholecystitis are seen. No evidence of pericholecystic fluid collection is seen. CBD appears normal.

**PANCREAS:** Pancreas appears normal in size and shows normal parenchymal echoes. No evidence of pancreatitis or pancreatic mass lesion is seen.

**SPLEEN:** Spleen appears normal in size and shows normal parenchymal echoes. No evidence of focal or diffuse lesion is seen.

**KIDNEYS:** Both kidneys are normal in size, shape and position. Both renal contours are smooth. Cortical and central echoes appear normal. Bilateral cortical thickness appears normal. No evidence of renal calculus, hydronephrosis or mass lesion is seen on either side. No evidence of perinephric fluid collection is seen.

Right kidney measures about 10.1 x 4.6 cms in size.

Left kidney measures about 10.6 x 4.8 cms in size.

No evidence of suprarenal mass lesion is seen on either side.

Aorta, IVC and para aortic region appears normal.

No evidence of ascites is seen.

**BLADDER:** Bladder is normally distended and appears normal. No evidence of bladder calculus, diverticulum or mass lesion is seen.

**PROSTATE:** Prostate appears normal in size and shows normal parenchymal echoes. No evidence of pathological calcification or solid or cystic mass lesion is seen. Prostate volume measures about 9 cc.

#### COMMENT:

- Fatty liver grade I.
- Normal sonographic appearance of GB, Pancreas, spleen, kidneys, para-aortic region, bladder and prostate.

  
**RADIOLOGIST**

**DR. MEHUL PATELIYA**

